NOT FDA-APPROVED · PHASE IIB ONLY · CARDIOVASCULAR MONITORING REQUIRED
Tesofensine elevates heart rate and blood pressure as class effects of triple monoamine reuptake inhibition. Baseline cardiovascular assessment before use and BP/HR monitoring during protocol is non-negotiable.
COMPOUND PROFILE · PEPPERLEDGER
Tesofensine
Neurosearch / Saniona · Originally developed for Parkinson's disease; obesity development after weight loss observed in Parkinson's trials
Tesofensine was originally developed by Neurosearch as a Parkinson's disease treatment — a neurological application targeting monoamine systems. In the Parkinson's trials, participants lost significant weight as a side effect. Neurosearch pivoted to obesity development, and the Phase IIb obesity trial (NN2330-1803) became one of the most-discussed weight loss drug trials of the late 2000s: 10.6% mean body weight loss over 24 weeks at 0.5 mg/day, with dose-dependent effects up to 12.8% at 1 mg/day.
The mechanism is triple monoamine reuptake inhibition — blocking the transporters for serotonin, dopamine, and norepinephrine simultaneously. This produces appetite suppression via central satiety signaling, increased basal metabolic rate via sympathetic nervous system activation, and dopaminergic reward pathway modulation that reduces food reward salience. The triple mechanism produces more robust weight loss than single or dual reuptake inhibitors (e.g., sibutramine, which was withdrawn over cardiovascular concerns).
Tesofensine was not pursued to Phase III by the original developer. It remains available as a research chemical. In the context of the current GLP-1 revolution, tesofensine occupies an interesting position: comparable weight loss magnitude to liraglutide (~10–11% vs. ~8%), faster onset (effects within weeks rather than months of gradual titration), but carrying cardiovascular risks that GLP-1 agonists do not — elevated heart rate and blood pressure from norepinephrine reuptake inhibition.
How it works
Triple Monoamine Reuptake Inhibition
Tesofensine blocks the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) — the same transporters targeted individually or in pairs by SSRIs, SNRIs, and bupropion. Blocking all three simultaneously produces: serotonergic satiety signaling (reduced appetite), dopaminergic reward pathway modulation (reduced food reward, altered eating behavior), and noradrenergic metabolic rate increase (elevated thermogenesis and energy expenditure via sympathetic activation).
Appetite Suppression via Central Satiety
The serotonin and norepinephrine components drive appetite suppression via hypothalamic satiety centers — the same mechanism exploited by older weight loss drugs (sibutramine). The dopamine component reduces the rewarding quality of food, changing the motivational relationship with eating rather than just creating satiety. This multi-axis appetite suppression is why the weight loss effect size exceeds single-mechanism reuptake inhibitors.
Long Half-Life — Practical Implications
Tesofensine's active metabolite has a half-life of approximately 220 hours (~9 days). Steady state takes approximately 3 weeks of daily dosing. This means: slow onset of full effect, slow offset if side effects develop — you cannot quickly stop and clear the compound. The very long half-life also means once-daily dosing produces stable plasma levels, avoiding the peaks and troughs of shorter-acting compounds.
What the research shows
PHASE IIB RCT DATA — MEANINGFUL HUMAN EVIDENCE, NO PHASE III
203 obese adults. Tesofensine 0.25, 0.5, or 1.0 mg daily vs. placebo for 24 weeks. Mean weight loss: 6.5% (0.25 mg), 11.3% (0.5 mg), 12.8% (1.0 mg) vs. 2.0% placebo. Elevated pulse rate and blood pressure at higher doses — the cardiovascular signal that required further investigation. Landmark Phase IIb data establishing the weight loss efficacy and the dose-limiting cardiovascular effects.
Tesofensine's community is primarily in the metabolic optimization and weight loss biohacker space — people who have specifically researched alternatives or complements to GLP-1 agonists, often those who didn't respond adequately to liraglutide or can't access semaglutide. The consistent community reports: significant and relatively rapid appetite suppression (effects within the first week at steady-state approach, faster than GLP-1's gradual titration), increased energy and motivation (consistent with dopamine and norepinephrine effects), and elevated resting heart rate — the most universally reported side effect, typically +5–10 bpm. Blood pressure monitoring is consistently discussed in community protocols as essential.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓10.6–11.3% mean weight loss at 0.5 mg over 24 weeks — Phase IIb RCT data (Lancet, 2008)
✓Triple reuptake inhibition mechanism well-characterized — SERT, DAT, NET blockade
✓Elevated heart rate and blood pressure are class effects — documented in Phase IIb, require monitoring
✓Very long half-life (~220 hours active metabolite) — slow onset, slow offset, 3 weeks to steady state
✓Appetite suppression and metabolic rate increase — consistent mechanistic and clinical data
?UNCERTAIN
?Long-term cardiovascular safety — Phase IIb was 24 weeks; no outcomes trial data
?Whether cardiovascular effects limit use in high-risk populations (they likely do)
?Phase III outcomes data — never completed; long-term weight maintenance and safety unknown
?Optimal dosing — 0.5 mg appears the balance point between efficacy and cardiovascular side effects, but individual variation is significant
?Interaction profile with GLP-1 agonists — some combine tesofensine with lower-dose GLP-1 for synergistic weight loss, but no formal data
AI COACH PREVIEW
I've been on semaglutide 1mg and lost 8% body weight but plateaued. I'm considering adding tesofensine. Is this a reasonable stack and how would I structure it?
The mechanistic case for the combination is reasonable — GLP-1 works primarily through peripheral satiety (gastric emptying, gut-brain axis), while tesofensine works through central monoamine systems (hypothalamic appetite suppression and dopaminergic reward modulation). They're complementary mechanisms, not redundant ones. The combination has been discussed in the literature as a potential approach to semaglutide non-responders or plateaus. Before anything else: cardiovascular baseline. Semaglutide at 1 mg is cardiovascular protective. Tesofensine elevates heart rate and blood pressure. Before adding a norepinephrine reuptake inhibitor to your stack, you need a current BP reading and resting HR. If your resting HR is already elevated (>75 bpm) or if you have hypertension, I'd be cautious about adding tesofensine. If your baseline is clean: start tesofensine at 0.25 mg daily for 3 weeks (approaching steady state), monitor HR and BP weekly, then consider stepping to 0.5 mg only if cardiovascular response is acceptable. On the plateau itself: before adding another compound, have you hit protein targets (1.4–1.6g/kg) and resistance training minimum (3x/week)? GLP-1 plateau is often addressable through these before escalating pharmacology.
CONTINUE IN THE APP
Open PepperLedger to track your tesofensine protocol →
Free to join. Monitor heart rate and blood pressure with every protocol update. The Coach understands how to structure tesofensine alongside GLP-1 protocols.
Free to join · No credit card · 23-day Pro trial included